DGX

Quest Diagnostics
D

DGX

Arincen63/100B

Quest Diagnostics stock buybacks 1996–2026

Quest Diagnostics spent 150.00M USD buying back its shares in Q3 FY2026, the three months to 30 September 2026, up 0.0% on the same quarter a year before. Quest Diagnostics spent 450.00M USD buying back its shares in fiscal year 2025, up 198.0% on the year before.

Last updated 7 Nov 2026 · Next report 9 Feb 2027

Stock buybacks

Growth

Fiscal yearPeriod endingStock buybacksGrowthDividends paidFree cash flow
TTM30 Sept 2026——369.00M1.38B
FY202531 Dec 2025450.00M+198.01%353.00M1.36B
FY202431 Dec 2024151.00M-45.09%331.00M909.00M
FY202331 Dec 2023275.00M-80.47%314.00M864.00M
FY202231 Dec 20221.41B-35.97%305.00M1.31B
FY202131 Dec 20212.20B+576.62%309.00M1.83B
FY202031 Dec 2020325.00M-7.93%297.00M1.59B
FY201931 Dec 2019353.00M+9.63%286.00M843.00M
FY201831 Dec 2018322.00M-30.75%266.00M817.00M
FY201731 Dec 2017465.00M-21.19%247.00M923.00M
FY201631 Dec 2016590.00M+163.39%223.00M776.00M
FY201531 Dec 2015224.00M+69.70%212.00M547.00M
FY201431 Dec 2014132.00M-87.27%187.00M630.00M
FY201331 Dec 20131.04B+418.50%185.00M421.00M
FY201231 Dec 2012200.00M-78.61%108.00M1.00B
FY201131 Dec 2011935.00M+24.67%65.00M734.00M
FY201031 Dec 2010750.00M+50.00%71.32M912.60M
FY200931 Dec 2009499.99M+96.85%110.27M830.50M
FY200831 Dec 2008254.00M+74.38%77.96M850.40M
FY200731 Dec 2007145.66M-69.16%77.33M707.82M
FY200631 Dec 2006472.33M+21.06%77.14M758.47M
FY200531 Dec 2005390.16M-46.89%69.67M627.31M
FY200431 Dec 2004734.58M+185.22%61.39M622.66M
FY200331 Dec 2003257.55M—0.00488.16M
FY200231 Dec 20020.00-100.00%0.00441.18M
FY200131 Dec 20011.00M—8.95M316.82M
FY200031 Dec 20000.00-100.00%6.90M253.01M
FY199931 Dec 19991.10M-91.54%100.00K-851.50M
FY199831 Dec 199813.00M—100.00K100.90M
FY199731 Dec 19970.00—100.00K129.50M
FY199631 Dec 19960.00—1.17M-158.88M

Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

The money spent buying back the company's own shares in each period, from the cash flow statement.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Cash flow

Common questions about Quest Diagnostics's buybacks

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.